Gender-dependent association of TYMS-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet. Genomics 21(4), 237–242 (2011).
  Medline CASGoogle Scholar
• 2. Kadoyama K, Miki I, Tamura T, Brown JB, Sakaeda T, Okuno Y. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int. J. Med. Sci. 9(1), 33–39 (2012).
  Medline CASGoogle Scholar
• 3. Lampropoulos S, Roditis P, Koulouris E et al. Report of two cases of acute cardiac adverse events in patients with colorectal carcinoma receiving oral capecitabine. Anticancer Drugs 28(7), 801–807 (2017).
  Medline CASGoogle Scholar
• 4. Desmoulin F, Gilard V, Malet-Martino M, Martino R. Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine. Drug Metab. Dispos. 30(11), 1221–1229 (2002).
  Medline CASGoogle Scholar
• 5. Amstutz U, Henricks LM, Offer SM et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin. Pharmacol. Ther. 103(2), 210–216 (2018). •• Provides information for the interpretation of clinical DPYD genotype tests so that the results can be used to guide dosing of 5-fluorouracil (5-FU) and capecitabine (CAP).
  Medline CASGoogle Scholar
• 6. Peters GJ, van der Wilt CL, van Triest B et al. Thymidylate synthase and drug resistance. Eur. J. Cancer 31A(7–8), 1299–1305 (1995). •• Describes resistance to 5-FU in several models and in patients, in relation to TS content and inhibition.
  Medline CASGoogle Scholar
• 7. Marsh S. Thymidylate synthase pharmacogenetics. Invest. New Drugs 23(6), 533–537 (2005).
  Medline CASGoogle Scholar
• 8. Ishida Y, Kawakami K, Tanaka Y, Kanehira E, Omura K, Watanabe G. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Anticancer Res. 22(5), 2805–2809 (2002). • Shows that tumors with TYMS 3R/3R genotype had higher TS protein expression than that with the 2R/3R genotype.
  Medline CASGoogle Scholar
• 9. National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50
  Google Scholar
• 10. Ragia G, Nikolaidis E, Tavridou A et al. Renin-angiotensin-aldosterone system gene polymorphisms in coronary artery bypass graft surgery patients. J. Renin Angiotensin. Aldosterone Syst. 11(2), 136–145 (2010).
  Medline CASGoogle Scholar
• 11. Ragia G, Nikolaidis E, Tavridou A et al. Endothelial nitric oxide synthase gene polymorphisms -786T > C and 894G > T in coronary artery bypass graft surgery patients. Hum. Genomics 4(6), 375–383 (2010).
  Medline CASGoogle Scholar
• 12. Misailidis G, Ragia G, Ivanova DD, Tavridou A, Manolopoulos VG. Gene-gene interaction of μ-opioid receptor and GluR5 kainate receptor subunit is associated with smoking behavior in a Greek population: presence of a dose allele effect. Drug Metab. Pers. Ther. 30(2), 129–135 (2015).
  Medline CASGoogle Scholar
• 13. Hishida A, Matsuo K, Hamajima N et al. Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. Haematologica 88(2), 159–166 (2003).
  Medline CASGoogle Scholar
• 14. Lincz LF, Scorgie FE, Garg MB, Ackland SP. Identification of a novel single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele. Int. J. Cancer 120(9), 1930–1934 (2007). •• Identifies G>C SNP in the first repeat of the TYMS 2R allele, which effectively abolishes the only functional USF protein binding site in this promoter.
  Medline CASGoogle Scholar
• 15. Weir BS. Disequilibrium. In: Genetic Data Analysis II. Sinauer Associates Inc., MA, USA, 91–139 (1996).
  Google Scholar
• 16. Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs 19(5), 447–464 (2008).
  Medline CASGoogle Scholar
• 17. van Beek MWH, Roukens M, Jacobs WCH, Timmer-Bonte JNH, Kramers C. Real-world adverse effects of capecitabine toxicity in an elderly population. Drugs Real World Outcomes 5(3), 161–167 (2018).
  MedlineGoogle Scholar
• 18. Kakolyris S, Souglakos J, Polyzos A et al. Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter Phase II study. Oncology 74(1–2), 31–36 (2008).
  Medline CASGoogle Scholar
• 19. Amarantidis K, Xenidis N, Chelis L et al. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors. Acta Oncol. 49(2), 245–251 (2010).
  Medline CASGoogle Scholar
• 20. Amarantidis K, Xenidis N, Chelis L et al. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer. Oncology 80(5–6), 359–365 (2011).
  Medline CASGoogle Scholar
• 21. Xenidis N, Chelis L, Amarantidis K et al. Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study. Cancer Chemother. Pharmacol. 69(2), 477–484 (2012).
  Medline CASGoogle Scholar
• 22. Ntavatzikos A, Spathis A, Patapis P et al. Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer. World J. Gastroenterol. 23(32), 5913–5924 (2017). • Shows the association of TYMS genotypes with worst prognosis in mCRC patients under fluoropyrimidine-based chemotherapy
  Medline CASGoogle Scholar
• 23. Ntavatzikos A, Spathis A, Patapis P et al. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer. World J. Gastrointest. Oncol. 11(7), 551–566 (2019).
  MedlineGoogle Scholar
• 24. Gallegos-Arreola MP, Zúñiga-González GM, Sánchez-López JY et al. TYMS 2R3R polymorphism and DPYD [IVS]14+1G>A gene mutation in Mexican colorectal cancer patients. Acta Biochim. Pol. 65(2), 227–234 (2018).
  Medline CASGoogle Scholar
• 25. Romiti A, Roberto M, D'Antonio C et al. The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer. Anticancer Drugs 27(10), 1044–1049 (2016).
  Medline CASGoogle Scholar
• 26. Schaerer D, Froehlich TK, Hamzic S et al. A novel nomenclature for repeat motifs in the thymidylate synthase enhancer region and its relevance for pharmacogenetic studies. J. Pers. Med. 10(4), 181 (2020).
  Google Scholar
• 27. Ichikawa W, Takahashi T, Suto K, Sasaki Y, Hirayama R. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin. Cancer Res. 12(13), 3928–3934 (2006).
  Medline CASGoogle Scholar
• 28. Schwab M, Zanger UM, Marx C et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 26(13), 2131–2138 (2008). • Multicenter prospective clinical trial shows that DPYD, TYMS and MTHFR play a role for FU-related toxicity
  Medline CASGoogle Scholar
• 29. Castro-Rojas CA, Esparza-Mota AR, Hernandez-Cabrera F et al. Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer. Drug Metab. Pers. Ther. 32(4), 209–218 (2017).
  Medline CASGoogle Scholar
• 30. Lecomte T, Ferraz JM, Zinzindohoué F et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin. Cancer Res. 10(17), 5880–5888 (2004).
  Medline CASGoogle Scholar
• 31. Pullarkat ST, Stoehlmacher J, Ghaderi V et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1(1), 65–70 (2001).
  Medline CASGoogle Scholar
• 32. Cho HJ, Park YS, Kang WK, Kim JW, Lee SY. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther. Drug Monit. 29(2), 190–196 (2007).
  Medline CASGoogle Scholar
• 33. Botticelli A, Onesti CE, Strigari L et al. A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient. Anticancer Drugs 28(5), 551–556 (2017).
  Medline CASGoogle Scholar
• 34. Loganayagam A, Arenas Hernandez M, Corrigan A et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br. J. Cancer 108(12), 2505–2515 (2013).
  Medline CASGoogle Scholar
• 35. Roberto M, Romiti A, Botticelli A et al. Evaluation of 5-fluorouracil degradation rate and pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. Eur. J. Clin. Pharmacol. 73(2), 157–164 (2017).
  Medline CASGoogle Scholar
• 36. Sharma R, Hoskins JM, Rivory LP et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin. Cancer Res. 14(3), 817–825 (2008).
  Medline CASGoogle Scholar
• 37. Joerger M, Huitema AD, Boot H et al. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother. Pharmacol. 75(4), 763–772 (2015).
  Medline CASGoogle Scholar
• 38. Tecza K, Pamula-Pilat J, Lanuszewska J, Butkiewicz D, Grzybowska E. Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget 9(10), 9114–9136 (2018).
  MedlineGoogle Scholar
• 39. Rosmarin D, Palles C, Church D et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J. Clin. Oncol. 32(10), 1031–1039 (2014). • Proposes a panel of genetic biomarkers that includes TYMS 3R/2R for CAP monotherapy toxicity.
  Medline CASGoogle Scholar
• 40. Jennings BA, Kwok CS, Willis G, Matthews V, Wawruch P, Loke YK. Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet. Genomics 22(4), 290–304 (2012).
  Medline CASGoogle Scholar
• 41. DiPaolo A, Chu E. The role of thymidylate synthase as a molecular biomarker. Clin. Cancer Res. 10(2), 411–412 (2004).
  Medline CASGoogle Scholar
• 42. Ngwenya S, Safe S. Cell context-dependent differences in the induction of E2F-1 gene expression by 17 beta-estradiol in MCF-7 and ZR-75 cells. Endocrinology 144(5), 1675–1685 (2003).
  Medline CASGoogle Scholar
• 43. Nakayama Y, Sakamoto H, Satoh K, Yamamoto T. Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system. Cancer Lett. 161(1), 63–71 (2000).
  Medline CASGoogle Scholar
• 44. Nanni S, Bacci L, Aiello A et al. Signaling through estrogen receptors modulates long non-coding RNAs in prostate cancer. Mol. Cell. Endocrinol. 511, 110864 (2020).
  Medline CASGoogle Scholar
• 45. Chen W, Xu XK, Li JL et al. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget 8(14), 22783–22799 (2017).
  MedlineGoogle Scholar
• 46. Fang Z, Wang Y, Wang Z et al. ERINA is an estrogen-responsive LncRNA that drives breast cancer through the E2F1/RB1 pathway. Cancer Res. 80(20), 4399–4413 (2020).
  Medline CASGoogle Scholar
• 47. Fernández-Contreras ME, Sánchez-Hernández JJ, Guijarro M et al. Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer. Oncol. Rep. 23(5), 1393–1400 (2010).
  Medline CASGoogle Scholar
• 48. Wang J, Wang B, Bi J, Di J. The association between two polymorphisms in the TYMS gene and breast cancer risk: a meta-analysis. Breast Cancer Res. Treat. 128(1), 203–209 (2011). • Meta-analysis shows that TYMS-TSER polymorphism may increase susceptibility to breast cancer in the Caucasian population.
  MedlineGoogle Scholar
• 49. Lin S, Yue J, Guan X et al. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer. Cancer Commun. (Lond). 39(1), 57 (2019).
  MedlineGoogle Scholar
• 50. Kumar K, Vamsy M, Jamil K. Thymidylate synthase gene polymorphisms effecting 5-FU response in breast cancer patients. Cancer Biomark. 6(2), 83–93 (2010).
  MedlineGoogle Scholar
• 51. Li J, Sun P, Huang T, He S, Li L, Xue G. Individualized chemotherapy guided by the expression of ERCC1, RRM1, TUBB3, TYMS and TOP2A genes versus classic chemotherapy in the treatment of breast cancer: a comparative effectiveness study. Oncol. Lett. 21(1), 21 (2021).
  MedlineGoogle Scholar
• 52. Largillier R, Etienne-Grimaldi MC, Formento JL et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin. Cancer Res. 12(18), 5496–5502 (2006).
  Medline CASGoogle Scholar